Clinical Trials on Primary Breast Cancer

Total 99371 results

Queen Mary University of London
Astellas Pharma Inc

Unknown

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)

Primary Breast Cancer ER+ve | Primary Breast Cancer AR+ve TNBN

Germany, United Kingdom, Spain, United States, Ireland
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Hoffmann-La Roche; Brigham and Women's...

Terminated

Capecitabine in Women With Operable Breast Cancer

Stage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage III Breast Cancer | Primary Invasive Breast Cancer

United States
University Health Network, Toronto

Completed

A Prototype Tri-modal Imaging Device for Breast Cancer

Breast Cancer Invasive Nos | Primary Invasive Breast Cancer

Canada
Kliniken Essen-Mitte

Recruiting

Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy (Ultra3Detect)

Primary Breast Cancer

Germany
Fudan University
Chinese Anti-Cancer Association

Completed

Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

Primary Breast Cancer

China
Fudan University

Completed

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Primary Breast Cancer
Klinikum Weissenfels

Completed

Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel (ETCat01)

Primary Breast Cancer

Germany
German Breast Group
German Adjuvant Breast Cancer Group

Completed

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

Primary Breast Cancer

Germany
RWTH Aachen University

Recruiting

mULM to Support Breast Cancer Diagnosis and Therapy

Primary Breast Cancer

Germany
Tao OUYANG
Peking University First Hospital; 307 Hospital of PLA; Peking University People... and other collaborators

Active, not recruiting

Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

Primary Breast Cancer

China
German Breast Group

Completed

Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)

Primary Breast Cancer

Germany
Tomsk National Research Medical Center of the Russian...

Recruiting

Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3

Primary Breast Cancer

Russian Federation
Tao OUYANG

Recruiting

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Primary Breast Cancer

China
Tomsk National Research Medical Center of the Russian...
Uppsala University; Institute of Bioorganic Chemistry, Russian Academy of Sciences

Completed

Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3 (HE3-G3)

Primary Breast Cancer

Russian Federation
University Hospital, Rouen

Completed

Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation (PANEL)

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Pediatric Cancers | Multiple Primary Malignant Tumours

France
Daiichi Sankyo, Inc.
AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...

Active, not recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

HER2-Positive Primary Breast Cancer | Residual Invasive Breast Cancer

United States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
Cancer Trials Ireland

Recruiting

Breast Cancer Proteomics and Molecular Heterogeneity

Primary Breast Cancer | Recurrent/Metastatic Breast Cancer

Ireland
West German Study Group
Teva Pharmaceuticals USA

Active, not recruiting

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

Early Primary Breast Cancer

Germany
Myriad Genetic Laboratories, Inc.

Terminated

EndoPredict® Extended Endocrine Trial (EXET)

Primary Invasive Breast Cancer

United States
RWTH Aachen University
Univ.-Prof. Dr. med. F. Kiessling

Unknown

KVUS at Neoadjuvant CTx of Breast Cancer

Early Primary Breast Cancer

Germany
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast Cancerv

United States
Istituto Scientifico Romagnolo per lo Studio e...

Completed

A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.

Women With Primary Breast Cancer

Italy
West German Study Group
Sanofi; Amgen

Completed

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer (planB)

Primary Breast Cancer | Her2 Non-overexpressing

Germany
Novartis Pharmaceuticals
Breast International Group; German Breast Group; SOLTI Breast Cancer Research...

Completed

NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer (NeoPHOEBE)

HER2-positive Newly Diagnosed, Primary Breast Cancer

Austria, Spain, Australia, Germany
Novartis Pharmaceuticals

Terminated

Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow (MRD-1)

Primary Breast Cancer

Germany
AstraZeneca

Completed

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer. (D6090C00002)

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Germany, United Kingdom
Mayo Clinic

Completed

Histology of Functional Density in Postmenopausal Breast

Breast Cancer | Dense Breasts

United States
Mayo Clinic

Completed

Histology of Functional Density in Premenopausal Breast

Breast Cancer | Dense Breasts

United States
National University Hospital, Singapore

Recruiting

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Advanced Refractory Solid Tumors | Advanced Triple Negative Breast Cancers | Metastatic Triple Negative Breast Cancers

Singapore
Kaplan Medical Center
Tel Aviv University; Rabin Medical Center; Tel-Aviv Sourasky Medical Center; Sheba...

Unknown

Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery

Primary Operable Breast Cancer

Israel
Avelas Biosciences, Inc.
Clinipace Worldwide; RRD International, Inc.

Completed

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Carcinoma, Ductal, Breast | Breast Cancer Female | Stage III Breast Cancer | Carcinoma Breast | Primary Invasive Malignant Neoplasm of Female Breast

United States
UNICANCER
Ministry of Health, France

Active, not recruiting

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Primary Non-metastatic Breast Cancer | Who Remain Disease-free

France
Novartis Pharmaceuticals

Terminated

A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss

Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women

Germany
Pfizer

Active, not recruiting

A Study of PF-06873600 in People With Cancer

HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

United States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
University of Roma La Sapienza

Completed

To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)

Stage I Breast Cancer | Cancer, Treatment-Related | Systemic Inflammatory Response | Tumor of Breast

Italy
British Columbia Cancer Agency
Janssen Research & Development, LLC

Withdrawn

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer

Canada
Novartis Pharmaceuticals
University of Sheffield; Danish Breast Cancer Cooperative Group

Completed

A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer

Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women

Denmark, United Kingdom
VelosBio Inc.

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Gastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditions

United States, Canada
Pamela Munster
Pfizer; Xynomic Pharmaceuticals, Inc.

Withdrawn

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
University of Michigan
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies

Breast Cancers

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Bone Metastases | Lung Metastases | HER2-positive Breast Cancer | Liver Metastases | Stage IV Breast Cancer | Recurrent Breast Cancer | Soft Tissue Metastases

United States
Jules Bordet Institute

Completed

Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers (MOMENTUM1)

Metastatic Colorectal Cancers | Metastatic Gastric Cancers | Metastatic Oesophageal Cancers | Metastatic Pancreatic Cancers | Metastatic Biliary Cancers | Metastatic Breast Cancers

Belgium
University of Chicago
National Cancer Institute (NCI)

Completed

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
Tao OUYANG

Recruiting

Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study) (COHAIR)

Primary Breast Cancer

China
University of Southern California
National Cancer Institute (NCI)

Terminated

Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors

Obesity | Overweight | Sedentary Lifestyle | Stage I Breast Cancer | Cancer Survivor | Prostate Carcinoma | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage... and other conditions

United States
Northwestern University
Eisai Inc.

Unknown

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...

United States
Weill Medical College of Cornell University
Avon Foundation

Completed

The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers

Gynecologic Cancer | Breast Cancers

United States
National Cancer Institute (NCI)

Completed

AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage...

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States

Clinical Trials on Primary Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations